Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5859992 | 0.98 | ALDH1A1 (0.50) | ALDH1A1NPSR1PKML3MBTL1KMT2A | |
| SCHEMBL163027 | 0.92 | NPSR1 (0.53) | ALDH1A1NPSR1PKMKMT2AGLA | |
| SCHEMBL12104078 | 0.91 | ALDH1A1 (0.48) | ALDH1A1NPSR1PKML3MBTL1KMT2A | |
| SCHEMBL5859987 | 0.85 | NPSR1 (0.47) | ALDH1A1NPSR1L3MBTL1KMT2AGLA | |
| SCHEMBL5859999 | 0.85 | NPSR1 (0.47) | ALDH1A1NPSR1KMT2AGLATHRB | |
| SCHEMBL5082232 | 0.85 | ALDH1A1 (0.39) | ALDH1A1NPSR1PKML3MBTL1KMT2A | |
| SCHEMBL5084537 | 0.85 | ALDH1A1 (0.39) | ALDH1A1NPSR1PKML3MBTL1KMT2A | |
| SCHEMBL164232 | 0.84 | L3MBTL1 (0.58) | ALDH1A1NPSR1PKML3MBTL1KMT2A | |
| SCHEMBL13589980 | 0.84 | L3MBTL1 (0.58) | ALDH1A1NPSR1PKML3MBTL1KMT2A | |
| SCHEMBL14493665 | 0.84 | L3MBTL1 (0.58) | ALDH1A1NPSR1PKML3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014119698-A1 | PATTERN FORMING METHOD, COMPOUND USED THEREIN, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2014-08-07 | — | — | WO | disclosed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| US-RE39744-E1 | Adamantane derivatives and process for producing them | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20070078256-A1 | Prepolymers, prepolymer compositions, high-molecular-weight polymers with pore structure, and dielectric films | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-7115768-B2 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1683822-A1 | PREPOLYMER, PREPOLYMER COMPOSITION, HIGH MOLECULAR WEIGHT POLYMER HAVING STRUCTURE CONTAINING HOLE AND ELECTRICALLY INSULATING FILM | Daicel Chemical Industries, Ltd. (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-7078562-B2 | Adamantane derivatives and resin compositions using the same as raw material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| US-20050158662-A1 | Adamantane derivatives and resin compositions using the same as raw material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1144364-B1 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | GRANT FRANCINE S (US) | 2003-07-17 | — | — | US | disclosed |
| US-6468487-B1 | SUCH AS N-HYDROXYPHTHALIMIDE; DIRECTLY AND EFFICIENTLY REACTING ADAMANTANE WITH NITROGEN OXIDE OR WITH CARBON MONOXIDE AND OXYGEN | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6465513-B1 | SUCH AS N-(ADAMANT-1-YLCARBONYL)-L-4-(N,N-DIMETHYLCARBAMYL-OXY)PHENYLALANINE; INFLAMMATORY DISEASES SUCH AS ASTHMA, AIDS DEMENTIA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6392104-B1 | CHEMICAL INTERMEDIATES FOR DRUGS, AGRICULTURE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| EP-1144364-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043354-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0927711-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM | Daicel Chemical Industries, Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0897747-A1 | NITRATION OR CARBOXYLATION CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | ALDH1A1 369/4885NPSR1 2950/4885PKM 2066/4885 |
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 258/4885NPSR1 1381/4885PKM 3133/4885 |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 258/4885NPSR1 1381/4885PKM 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.